Clinical Trials Logo

Clinical Trial Summary

A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.


Clinical Trial Description

Sample size: 20 patients Study duration: 16 weeks Primary Endpoints: Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 4 compared to Baseline. Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 12 compared to Baseline. Secondary Endpoints: Safety and Tolerability (Grade 2/3 Adverse Effects); Changes in Disease Activity (Measures by AN count and IHS4 scoring). Study procedures Clinical Examination, Patient Questionnaires, Skin Biopsy, Blood Draw, medical photography ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05040698
Study type Interventional
Source Holdsworth House Medical Practice
Contact Trina Vincent, R.N.
Phone +61280381044
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Not yet recruiting NCT04132388 - Hidradenitis Suppurativa Patient Experience With Humira Treatment Phase 4
Not yet recruiting NCT05020730 - Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa Phase 2
Not yet recruiting NCT04388163 - Gentian Violet Treatment for Hidradenitis Suppurativa Phase 2
Not yet recruiting NCT04061395 - Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. Phase 2
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Not yet recruiting NCT04988308 - A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Recruiting NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2
Not yet recruiting NCT04582669 - Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa Phase 4
Not yet recruiting NCT04414514 - Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment Phase 2
Completed NCT01516749 - Anakinra as a Treatment for Hydradenitis Suppurativa Phase 2